

Resource Summary Report

Generated by [RRID](#) on Aug 28, 2026

GL261

RRID:CVCL_Y003

Type: Cell Line

Proper Citation

CLS Cat# 305225, RRID:CVCL_Y003

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_Y003

Proper Citation: CLS Cat# 305225, RRID:CVCL_Y003

Description: Cell line GL261 is a Cancer cell line with a species of origin Mus musculus (Mouse)

Disease: Mouse glioblastoma

Defining Citation: [PMID:16734735](#), [PMID:23248259](#), [PMID:23686484](#), [PMID:25894527](#), [PMID:30084848](#), [PMID:30524896](#)

Category: Cancer cell line

Organism: Mus musculus (Mouse)

Name: GL261

Synonyms: Glioma 261, GLIOMA 261, Glioma-261, GL-261

Cross References: BTO:BTO_0006483, BCRJ:0299, ChEMBL-Cells:ChEMBL4483160, ChEMBL-Targets:ChEMBL4483239, CLS:305225, DSMZ:ACC-802, DSMZCellDive:ACC-802, NCI-DTP:Glioma 261, PRIDE:PXD000589, PRIDE:PXD008733, PubChem_Cell_line:CVCL_Y003, Wikidata:Q27547979

ID: CVCL_Y003

Vendor: CLS

Catalog Number: 305225

Record Creation Time: 20250423T095646+0000

Record Last Update: 20260816T002349+0000

Ratings and Alerts

No rating or validation information has been found for GL261.

No alerts have been found for GL261.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 506 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Zhang Y, et al. (2026) Engineered probiotics recruit CAR macrophages and establish immune memory to eradicate heterogeneous glioblastoma in mice. *Cell host & microbe*, 34(2), 212.

Weng YS, et al. (2026) An IL-15 fusion with albumin-binding domain boosts immunotherapy therapy in glioblastoma via FGF-2 competition regulating FGFR1/2. *Cancer letters*, 657, 218694.

Zhang B, et al. (2026) Mitochondrial protein carboxyl-terminal alanine-threonine tailing promotes human glioblastoma growth by regulating mitochondrial function. *eLife*, 13.

Ahmad F, et al. (2026) Systemic cyst(e)inase administration induces ferroptosis and synergizes with temozolomide in glioblastoma. *iScience*, 29(1), 114350.

Young JS, et al. (2026) IL6 Supports Development of an Immunosuppressive Microenvironment and Resistance to Therapy in Glioblastoma. *Cancer research*, 86(14), 3570.

Lu Y, et al. (2026) Neuron-glioma synaptic transmission amplified by free 19S proteasome-mediated AMPAR deubiquitination promotes tumor progression. *Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics*, 23(1), e00847.

He ZNT, et al. (2026) H2S induces apoptosis of tumors with high IDO1 expression via NR4A1-BCL-2 and SOCS3 pathways. *Cellular & molecular biology letters*, 31(1).

Qian J, et al. (2026) Disease-associated microglia adopt stage-specific phenotypes that regulate T cell fate and immunity in glioma. *Immunity*.

Krattli RP, et al. (2026) C5aR1 Inhibition Alleviates Cranial Radiation-Induced Cognitive Decline. *Cancer research*, 86(1), 255.

Liu L, et al. (2026) Engineered Small Extracellular Vesicles Targeting Tumor-Associated Endothelial Cells to Effectively Remodel the Glioma Microenvironment. *Advanced science*

(Weinheim, Baden-Wurttemberg, Germany), 13(18), e18490.

Shen Y, et al. (2026) CCL1-AMFR Facilitates Glioblastoma Progression by Modulating the Cross-talk between Glioma Cells and Tumor-Associated Macrophages. *Cancer immunology research*, 14(4), 676.

Clubb JD, et al. (2026) Armored Chimeric Antigen Receptor T-cell Therapy Targets Antigen-Heterogeneous Glioma. *Cancer research*, 86(15), 3781.

Zhang L, et al. (2026) ZBTB7B inhibits glioma tumorigenicity by upregulating GPR17 and CXCL10. *Journal of molecular cell biology*, 17(11).

Zhou S, et al. (2026) Vascular normalization by erianin unleashes CAR-T immunotherapy in glioblastoma. *Angiogenesis*, 29(2), 18.

Sahu AP, et al. (2026) Tumor-associated macrophages promote ferroptosis resistance in glioblastoma by stimulating iron-loaded extracellular vesicle release. *Journal of neuro-oncology*, 177(2).

Lu B, et al. (2026) Targeting the tumor microenvironment: reprogramming macrophages as a novel therapeutic strategy in FUOM-deficient glioblastoma. *Cell death & disease*, 17(1).

Xiong T, et al. (2026) Small-Molecule Boron-10-Enriched Carriers with Exceptional Aqueous Solubility for Enhanced Boron Neutron Capture Therapy of Malignant Tumors. *Research (Washington, D.C.)*, 9, 1315.

Zhang C, et al. (2025) Self-Assembling Nanoparticles Orchestrate Cuproptosis-Immunotherapy Synergy to Suppress Postoperative Glioma Recurrence. *ACS applied materials & interfaces*, 17(47), 64322.

Huang H, et al. (2025) Targeted delivery of PTX by lactoferrin-modified nanoemulsions for the treatment of glioblastoma. *International journal of pharmaceutics*: X, 10, 100460.

Scafidi A, et al. (2025) Protocol for the generation and assessment of functional macrophages from mouse bone marrow cells. *STAR protocols*, 6(2), 103706.